Neuroanesthesia & neurocritical care
Cyclosporine versus placebo pretreatment of brain-dead donors and kidney graft function (Cis-A-Rein trial): a multicenter, double-blind, randomized, controlled trial
An erratum to this article was published (Intensive Care Med, Mar 2026 ↗)
Primary result · DGFResult — go to the resultUnadjusted odds ratio 1.27 95% CI 0.83–1.95Authors' conclusion
In this double-blind, randomized controlled clinical trial, a pretreatment of brain-dead donors with a single low dose of cyclosporine did not significantly reduce the occurrence of DGF in kidney transplant recipients.
Study context
- Population
- Brain-dead kidney donors and their kidney transplant recipientsmodified ITT analysis
- Comparison
- Cyclosporine 2.5 mg/kg vs glucose placebo infusion in brain-dead donors
- Cyclosporinen = 238 donors/312 recipients
- Placebon = 258 donors/331 recipientsreference
- Primary endpoint
- Delayed graft function (DGF): need for ≥1 hemodialysis within 7 days after kidney transplantation
- Follow-up
- 7 days
Methodological detailsmulticentre, double-blind, placebo-controlled, Enrolment December 17, 2017 to March 3, 2023
- Multicentre
- Double-blind
- Placebo-controlled
- Enrolment December 17, 2017 to March 3, 2023
Primary result
DGF
Unadjusted odds ratio
1.27
95% CI 0.83–1.95
P = 0.28
Events by treatment group
Cyclosporine vs Placebo
unadjusted OR 1.27 (95% CI 0.83–1.95); P = 0.28
As reported in the abstract
Secondary outcomes
Early graft function and 1-year graft and recipient survival
- No significant between-group differences
Original publication
Cyclosporine versus placebo pretreatment of brain-dead donors and kidney graft function (Cis-A-Rein trial): a multicenter, double-blind, randomized, controlled trial. Intensive Care Med. Published 8 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →